South African regulators decided Vertex Pharmaceuticals has provided sufficient access to its cystic fibrosis medications, ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

HHMI will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for funds to ...

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short ...

Happy birthday to Taylor Swift! She’s now old enough to run for president of the United States (not saying she SHOULD, just ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

SAN DIEGO — Brian Koffman found himself in a situation a couple years ago that most chronic lymphocytic leukemia patients ...

Kaadan is an assistant professor and vascular medicine attending in the cardiology division at Rush University Medical Center ...

Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...